Skip to content
Search

Latest Stories

REACTION: NHS frontline bodies welcome short-term budget boost, but seeks long-term allocation

The NHS frontline organisations - NHS Confederation and NHS Providers have welcomed the government’s decision to set aside additional £5.4 billion over the next six months for the NHS to cover additional costs from the coronavirus pandemic and to tackle the huge treatment backlog.

The two bodies have also sought urgent attention towards long-term funding requirement of the NHS.


They lauded the clarity given by the prime minister Boris Johnson and health secretary Sajid Javid regarding the additional funding.

“This funding will go straight to the frontline, to provide more patients with the treatments they need but aren’t getting quickly enough,” Johnson said in a statement.

Commenting on the announcement Matthew Taylor, chief executive of the NHS Confederation, and Saffron Cordery, deputy chief executive of NHS Providers, said: “The NHS can now get on with the huge task it has ahead of what we anticipate will be one of the most challenging winters the service has ever faced.

“The task for the government now is to follow up in its spending review with the extra £10bn a year the NHS will need over the next three years to avoid patient services from being cut.”

The NHS Confederation, which represents organisations across the healthcare sector, warned last week that the health service will need about £10bn more a year to reduce the Covid-19 backlog and cover additional costs from the pandemic.

With the clarity on funding, hospital, ambulance, mental health, community and primary care services can now plan their services, but staff shortages will make it much harder to clear the backlog.

“This isn’t a short-term fix – we are looking at five to seven years to clear the backlog,” the two bodies said in a joint statement.

Negating the media reports, it added that GP surgeries have remained open throughout the pandemic and will continue to provide face-to-face assessments when needed.

“The coming winter is going to be incredibly tough, but we have a chance of getting through this if the government, NHS and public continue to work together to manage the ongoing threat from Covid while starting to make inroads into the backlog of care.”

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less